0
0
NEW DELHI — In a major move to reshape how essential medicines are made, the Technology Development Board (TDB) of India’s Department of Science & Technology announced on June 4, 2026, its financial and strategic support for Chennai-based biotech firm Bioneemtec India Private Limited. The partnership aims to commercialize homegrown “green chemistry” technologies to manufacture critical active pharmaceutical ingredients (APIs) and advanced drug delivery systems. By utilizing cleaner, more efficient manufacturing methods, the initiative seeks to reduce India’s heavy reliance on imported medical raw materials, lower production waste, and secure the supply chain for widely used treatments ranging from hair loss to cancer therapies.
Shifting from Wasteful “Batch” to Sustainable “Flow” Chemistry
For decades, global pharmaceutical manufacturing has relied on traditional “batch processing”—a method akin to baking a cake, where ingredients are mixed in large vats, reacted, and emptied out step-by-step. While effective, batch manufacturing often generates substantial chemical waste and requires large amounts of energy and solvent.
Bioneemtec’s newly supported project introduces a hybrid model, combining advanced batch systems with continuous-flow chemistry. In flow chemistry, chemical reactions take place continuously within a network of narrow tubes or microreactors. This method allows for precise control over temperature and mixing, resulting in faster reaction times, significantly less chemical waste, and a safer working environment because smaller volumes of hazardous materials are handled at any given time.
Traditional Batch Processing: [Ingredients] -> [Large Vat Reaction] -> [Empty & Purify] -> [High Waste]
Continuous-Flow Chemistry: [Inputs] ───> [Controlled Microreactors] ───> [Pure API] ───> [Low Waste]
The Critical Medicines Moving to Local Production
The joint initiative focuses on securing and greening the supply chains for three highly in-demand medical compounds:
1. Tranexamic Acid (TXA)
Tranexamic acid is an essential medication used to prevent and treat severe blood loss. It is routinely utilized in trauma care, major surgeries, and postpartum hemorrhage—a leading cause of maternal mortality globally. Bioneemtec has developed an indigenous, cost-effective synthesis route that delivers high-purity TXA while minimizing chemical byproduct generation.
2. Minoxidil
Widely recognized as an over-the-counter topical treatment for hair loss (alopecia), minoxidil is also used in oral forms as a potent antihypertensive medication to treat severe high blood pressure. Localizing its key chemical intermediates helps protect domestic consumer and patient access from global supply chain shocks.
3. Dequalinium Chloride
This compound is a potent antiseptic and antimicrobial agent found in throat lozenges and topical wound treatments, and it is increasingly prescribed as a targeted vaginal infection treatment. Localizing its production strengthens the domestic supply of everyday infectious disease treatments.
Advanced Nanotechnology: Liposomes and Targeted Cancer Therapy
Beyond standard ingredient manufacturing, a standout element of the state-supported project is Bioneemtec’s proprietary Drug Liposome platform.
Liposomes are microscopic, spherical vesicles (bubbles) made out of the same material as cell membranes. In medicine, scientists use these tiny bubbles as delivery vehicles to encapsulate drugs. By wrapping a chemotherapy drug inside a liposome, the medicine can circulate through the bloodstream undetected by healthy tissue, releasing its therapeutic payload directly at the tumor site.
The company’s advanced nanotechnology platform has demonstrated promising results in maintaining controlled nanoparticle characteristics, with initial research targeting applications in breast and skin cancer management. Bioneemtec has initiated intellectual property (IP) protection for these formulations, laying the groundwork for affordable, locally produced targeted therapies.
Expert Perspectives and Public Health Implications
Public health experts not involved in the project view the government’s backing as a necessary step toward long-term healthcare security.
“The COVID-19 pandemic exposed severe vulnerabilities in the global pharmaceutical supply chain, particularly regarding our reliance on single-country sources for active pharmaceutical ingredients,” said Dr. Arisudan Dwivedi, a public health policy analyst based in New Delhi. “By scaling up green, continuous manufacturing domestically, India is not just protecting its environment; it is creating a highly resilient safety net for critical life-saving medications like Tranexamic acid.”
From an environmental standpoint, green chemistry represents a crucial evolution for the pharmaceutical sector, which historically carries a high carbon and chemical waste footprint.
“The transition to flow chemistry is a win-win for public health,” noted Dr. Sunanda Rao, an independent industrial chemist. “It drastically reduces the use of toxic organic solvents and curtails hazardous emissions. However, the true test will be scaling these micro-reactors from small laboratory environments to massive commercial outputs without losing the purity advantages.”
Balancing Expectations: Challenges Ahead
While the technology holds immense promise, industry analysts urge realistic timelines. Transitioning a pharmaceutical pipeline from traditional batch systems to continuous-flow systems involves stringent regulatory scrutiny. Every modified synthesis route must undergo rigorous validation to prove that the final drug molecule is structurally identical to, and as safe as, the conventionally manufactured version.
Furthermore, establishing new manufacturing facilities and scaling up nanomaterials like liposomes requires significant capital expenditure and a highly specialized workforce, meaning consumers may not see the direct cost-reduction benefits on pharmacy shelves immediately.
What This Means for Healthcare Providers and Consumers
For doctors and pharmacists, this development signals a future with fewer drug shortages for everyday essentials and critical trauma medicines. For health-conscious consumers, it highlights a growing alignment between medical efficacy and environmental sustainability. As India commercializes these indigenous technologies, patients may ultimately gain access to more stable supplies of high-purity, sustainably produced medications.
“The future of pharmaceutical manufacturing lies in sustainable, technology-driven production systems that combine quality, efficiency, and environmental responsibility,” stated Shri Rajesh Kumar Pathak, Secretary of the Technology Development Board (TDB). “TDB is committed to supporting such innovative enterprises that are creating high-value technologies while contributing to import substitution and healthcare security.”
Reference Section
-
Primary Source: Press Information Bureau (PIB) Delhi, Government of India. Department of Science & Technology / Technology Development Board. Announcement posted on 04 June 2026: “TDB-DST supports M/s Bioneemtec India Private Limited, Chennai for Commercialization of Green Chemistry-Based Pharmaceutical Manufacturing Technologies.”
- Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
